Abstract
PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).
RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.
SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.
| Original language | English |
|---|---|
| Pages (from-to) | 502-508 |
| Number of pages | 7 |
| Journal | Current Opinion in Allergy and Clinical Immunology |
| Volume | 18 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Allergen immunotherapy as add-on to biologic agents. / Lombardi, Carlo; Canonica, Giorgio W.; Passalacqua, Giovanni.
In: Current Opinion in Allergy and Clinical Immunology, Vol. 18, No. 6, 01.12.2018, p. 502-508.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Allergen immunotherapy as add-on to biologic agents
AU - Lombardi, Carlo
AU - Canonica, Giorgio W.
AU - Passalacqua, Giovanni
PY - 2018/12/1
Y1 - 2018/12/1
N2 - PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.
AB - PURPOSE OF REVIEW: In this review, we sought to outline many of the recent evidences about the available clinical trials in which biologic agents [i.e. omalizumab (OMA)] were associated as add-on to allergen-specific immunotherapy (AIT).RECENT FINDINGS: The available literature shows that OMA may be a valuable option as add-on to AIT for respiratory allergy, or food desensitization, especially in the escalation or build-up phases, in which adverse events are more commonly expected. The encouraging data for hymenoptera venom allergy remain limited to case reports, and no structured clinical trial is available.SUMMARY: Over the past decade, studies of OMA used with AIT have shown promising results. Today, big randomized, double-blind, placebo-controlled trials are needed to better select those patients who would benefit from the addition of OMA (or other biologic agents) to AIT, as well as optimal dosing schedules, optimal duration of treatments and, finally, adequate evaluation about pharmacoeconomic aspects.
UR - http://www.scopus.com/inward/record.url?scp=85055910333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055910333&partnerID=8YFLogxK
U2 - 10.1097/ACI.0000000000000479
DO - 10.1097/ACI.0000000000000479
M3 - Article
C2 - 30148718
AN - SCOPUS:85055910333
VL - 18
SP - 502
EP - 508
JO - Current Opinion in Allergy and Clinical Immunology
JF - Current Opinion in Allergy and Clinical Immunology
SN - 1528-4050
IS - 6
ER -